Adjuvant trastuzumab benefit in human epidermal growth factor receptor 2 (HER2)-positive lobular breast carcinoma compared to HER2-positive ductal carcinoma was evaluated. A higher recurrence rate in lobular as opposed to ductal disease in the pretrastuzumab era was observed, but no difference regarding histology was found in patients treated with adjuvant trastuzumab. An exploratory molecular analysis found high mutation load in lobular carcinoma. Background: Infiltrating lobular carcinoma (ILC) represents about 10% of breast cancer and rarely shows overexpression of human epidermal growth factor receptor 2 (HER2). We compared biological and clinical characteristics of HER2-positive ILC versus HER2-positive infiltrating ductal carcinoma (IDC). Patients and Methods: We retrospectively analyzed the data of 328 patients with HER2-positive pure ductal or lobular breast carcinoma, comparing clinical and biological data at diagnosis as well as outcome between the 2 histologies. A gene-mutation analysis was performed in a subset of patients. Results: Two hundred ninety-one patients (88.7%) had IDC and 37 patients (11.3%) ILC. ILC resulted more frequently in multicenter (24.3% vs. 6.5%, P < .0001) and node-positive (54.1% vs. 45%, P = .013) disease of lower proliferative activity (Mib1 < 20%: 51.4% vs. 22.3%, P < .0001) and lower histologic grade (grade 3: 32.4% vs. 57.4%, P = .038). Disease recurred in 57 patients (17.4%) and involved the bone in 40% of ILC patients (vs. 17% of IDC patients) and the viscera in 30% of ILC patients (vs. 59.6% of IDC patients). No difference in the recurrence rate between the 2 histologies was observed in patients treated with adjuvant trastuzumab (12.5% of ILC patients and 8.3% of IDC patients). Exploratory molecular analysis revealed a higher frequency of mutations in ILC, with more cases of multiple mutations. Conclusion: HER2-positive ILC shows different biological behavior than IDC, with a possible higher mutation load. Despite lower proliferation activity and estrogen receptor expression in ILC breast cancer, trastuzumab is clearly an effective therapy for this histologic subtype.

HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights

Da Ros, Lucia
Primo
;
Moretti, Anna;Querzoli, Patrizia;Pedriali, Massimo;Lupini, Laura;Bassi, Cristian;Carcoforo, Paolo;Negrini, Massimo
Penultimo
;
Frassoldati, Antonio
Ultimo
2018

Abstract

Adjuvant trastuzumab benefit in human epidermal growth factor receptor 2 (HER2)-positive lobular breast carcinoma compared to HER2-positive ductal carcinoma was evaluated. A higher recurrence rate in lobular as opposed to ductal disease in the pretrastuzumab era was observed, but no difference regarding histology was found in patients treated with adjuvant trastuzumab. An exploratory molecular analysis found high mutation load in lobular carcinoma. Background: Infiltrating lobular carcinoma (ILC) represents about 10% of breast cancer and rarely shows overexpression of human epidermal growth factor receptor 2 (HER2). We compared biological and clinical characteristics of HER2-positive ILC versus HER2-positive infiltrating ductal carcinoma (IDC). Patients and Methods: We retrospectively analyzed the data of 328 patients with HER2-positive pure ductal or lobular breast carcinoma, comparing clinical and biological data at diagnosis as well as outcome between the 2 histologies. A gene-mutation analysis was performed in a subset of patients. Results: Two hundred ninety-one patients (88.7%) had IDC and 37 patients (11.3%) ILC. ILC resulted more frequently in multicenter (24.3% vs. 6.5%, P < .0001) and node-positive (54.1% vs. 45%, P = .013) disease of lower proliferative activity (Mib1 < 20%: 51.4% vs. 22.3%, P < .0001) and lower histologic grade (grade 3: 32.4% vs. 57.4%, P = .038). Disease recurred in 57 patients (17.4%) and involved the bone in 40% of ILC patients (vs. 17% of IDC patients) and the viscera in 30% of ILC patients (vs. 59.6% of IDC patients). No difference in the recurrence rate between the 2 histologies was observed in patients treated with adjuvant trastuzumab (12.5% of ILC patients and 8.3% of IDC patients). Exploratory molecular analysis revealed a higher frequency of mutations in ILC, with more cases of multiple mutations. Conclusion: HER2-positive ILC shows different biological behavior than IDC, with a possible higher mutation load. Despite lower proliferation activity and estrogen receptor expression in ILC breast cancer, trastuzumab is clearly an effective therapy for this histologic subtype.
2018
Da Ros, Lucia; Moretti, Anna; Querzoli, Patrizia; Pedriali, Massimo; Lupini, Laura; Bassi, Cristian; Carcoforo, Paolo; Negrini, Massimo; Frassoldati, Antonio
File in questo prodotto:
File Dimensione Formato  
DaRos2018 1-s2.0-S1526820917302811-main.pdf

solo gestori archivio

Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 376.53 kB
Formato Adobe PDF
376.53 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
daros2018.pdf

accesso aperto

Tipologia: Post-print
Licenza: PUBBLICO - Pubblico con Copyright
Dimensione 1.1 MB
Formato Adobe PDF
1.1 MB Adobe PDF Visualizza/Apri

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2399755
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 9
social impact